L.G. Bernier et al.
Protides Biol. Fluid Proc. Colloq., 31, 787-787 (1983)
Andrew Howman et al.
Lancet (London, England), 381(9868), 744-751 (2013-01-15)
Membranous nephropathy leads to end-stage renal disease in more than 20% of patients. Although immunosuppressive therapy benefits some patients, trial evidence for the subset of patients with declining renal function is not available. We aimed to assess whether immunosuppression preserves...
Emanuele Zucca et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(5), 565-572 (2013-01-09)
Apart from localized gastric disease, there is no consensus on standard initial treatment of mucosa-associated lymphoid tissue lymphoma. The IELSG-19 study (Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma) was launched to compare chlorambucil alone...
Melissa Millard et al.
Journal of medicinal chemistry, 56(22), 9170-9179 (2013-10-24)
Nitrogen mustards, widely used as chemotherapeutics, have limited safety and efficacy. Mitochondria lack a functional nucleotide excision repair mechanism to repair DNA adducts and are sensitive to alkylating agents. Importantly, cancer cells have higher intrinsic mitochondrial membrane potential (Δψmt) than...
David G Oscier et al.
Blood, 121(3), 468-475 (2012-10-23)
NOTCH1 and SF3B1 mutations have been previously reported to have prognostic significance in chronic lymphocytic leukemia but to date they have not been validated in a prospective, controlled clinical trial. We have assessed the impact of these mutations in a...